Randomised controlled trial (RCT) assessed impact of two glucose monitoring systems on hypoglycaemia in people with type 1 diabetes EDINBURGH, Scotland, Jan. 30, 2018 /PRNewswire/ -- DexCom, Inc.
Investors misunderstand DXCM's recent revenue growth as a function of significant user adoption. Our research suggests one-off pre-buying of extendable sensors ahead of a big price increase. DXCM is ...
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Treatments for Type 2 diabetes and new clinical trial data ...
This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes. The ...
The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback